CRSP

CRISPR Therapeutics AG NASDAQ

Healthcare ·Biotechnology ·CH · crisprtx.com

$53.58

Mkt Cap $5.2B

52w Low $33.03 45.2% of range 52w High $78.48

50d MA $52.47 200d MA $56.46

P/E (TTM) -8.0x

EV/EBITDA -8.7x

P/B 2.4x

Debt/Equity 0.2x

ROE -30.3%

P/FCF -13.6x

RSI (14) —

ATR (14) —

Beta 1.79

50d MA $52.47

200d MA $56.46

Avg Volume 1.9M

About

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 12, 2026	AMC	-1.15	-1.37	-19.1%	48.93	+1.7%	+8.5%	+8.7%	+9.4%	+11.7%	+9.3%	-1.0%	—
Nov 10, 2025	AMC	-1.26	-1.17	+7.1%	54.58	-0.7%	+1.2%	-4.4%	-6.4%	-3.8%	+1.4%	+5.5%	—
Aug 4, 2025	AMC	-1.47	-1.29	+12.2%	59.59	-8.9%	-6.7%	-5.5%	-6.1%	-7.7%	-7.0%	-11.1%	—
May 6, 2025	AMC	-1.27	-1.58	-24.4%	33.16	+4.1%	+3.3%	+9.0%	+7.4%	+13.4%	+12.2%	+16.3%	—
Feb 11, 2025	AMC	-1.15	-0.44	+61.7%	39.62	+2.7%	+9.3%	+9.8%	+25.5%	+31.8%	+33.8%	+6.0%	—
Nov 5, 2024	AMC	-1.33	-1.01	+24.1%	50.36	+2.9%	+0.7%	+3.0%	+2.5%	+8.9%	+0.7%	-1.7%	—
Aug 5, 2024	AMC	-1.37	-1.49	-8.8%	49.66	+1.1%	-0.7%	-4.8%	-3.6%	-5.3%	-5.5%	-9.3%	—
May 8, 2024	AMC	-1.63	-1.43	+12.3%	53.29	-2.2%	+0.5%	-4.0%	+4.4%	+4.5%	+6.9%	+8.6%	—
Feb 21, 2024	AMC	-0.07	1.10	+1671.4%	82.41	-0.5%	+4.6%	+1.9%	+4.4%	+8.1%	+6.4%	-13.1%	—
Nov 6, 2023	AMC	-1.98	-1.41	+28.8%	51.58	+1.7%	+13.6%	+6.1%	-0.6%	+3.1%	+0.8%	+37.9%	—
Aug 7, 2023	AMC	-2.18	-0.98	+55.0%	48.34	+1.9%	+9.7%	+5.4%	+3.6%	+2.7%	+0.2%	+5.7%	—
May 8, 2023	AMC	-1.67	-0.67	+59.9%	55.96	+0.9%	+13.3%	+21.1%	+18.0%	+14.2%	+17.9%	+12.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 17	Piper Sandler	Maintains	Overweight → Overweight	—	$48.42	$48.90	+1.0%	+3.4%	-1.5%	-3.0%	-4.5%	-3.2%
Feb 17	Chardan Capital	Maintains	Buy → Buy	—	$53.07	$53.00	-0.1%	+0.2%	+0.8%	+3.0%	+0.7%	+1.7%
Feb 13	Evercore ISI	Maintains	Outperform → Outperform	—	$48.93	$49.74	+1.7%	+8.5%	+8.7%	+9.4%	+11.7%	+9.3%
Feb 13	TD Cowen	Maintains	Hold → Hold	—	$48.93	$49.74	+1.7%	+8.5%	+8.7%	+9.4%	+11.7%	+9.3%
Feb 13	Needham	Maintains	Buy → Buy	—	$48.93	$49.74	+1.7%	+8.5%	+8.7%	+9.4%	+11.7%	+9.3%
Jan 30	Citizens	Maintains	Market Outperform → Market Outperform	—	$53.35	$52.12	-2.3%	-6.4%	-3.8%	-2.5%	-6.0%	-14.0%
Dec 23	Needham	Maintains	Buy → Buy	—	$57.91	$57.10	-1.4%	-2.5%	-2.1%	-4.9%	-6.8%	-8.2%
Dec 23	Citizens	Maintains	Market Outperform → Market Outperform	—	$57.91	$57.10	-1.4%	-2.5%	-2.1%	-4.9%	-6.8%	-8.2%
Nov 26	Chardan Capital	Maintains	Buy → Buy	—	$53.57	$53.63	+0.1%	-0.5%	-0.2%	-2.6%	-3.7%	+4.5%
Nov 12	Citigroup	Maintains	Buy → Buy	—	$55.21	$55.31	+0.2%	-5.5%	-7.4%	-4.9%	+0.2%	-3.2%
Nov 11	Baird	Maintains	Neutral → Neutral	—	$54.58	$54.18	-0.7%	+1.2%	-4.4%	-6.4%	-3.8%	+1.4%
Nov 11	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$54.58	$54.18	-0.7%	+1.2%	-4.4%	-6.4%	-3.8%	+1.4%
Nov 10	Needham	Maintains	Buy → Buy	—	$55.12	$58.06	+5.3%	-1.0%	+0.2%	-5.3%	-7.3%	-4.7%
Oct 17	BofA Securities	Maintains	Buy → Buy	—	$68.43	$67.55	-1.3%	+1.1%	+8.1%	+5.7%	-2.8%	-1.8%
Oct 10	Needham	Maintains	Buy → Buy	—	$74.92	$77.33	+3.2%	-2.5%	-8.8%	-7.4%	-4.1%	-8.7%
Sep 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$62.10	$61.63	-0.8%	-2.2%	-1.7%	-2.9%	-0.7%	+2.7%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$56.34	$56.35	+0.0%	-0.7%	-2.4%	-1.7%	+0.5%	+1.8%
Aug 6	Barclays	Maintains	Equal Weight → Equal Weight	—	$55.59	$55.59	+0.0%	+1.3%	+0.7%	-1.1%	-0.3%	+1.8%
Aug 5	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$59.59	$54.30	-8.9%	-6.7%	-5.5%	-6.1%	-7.7%	-7.0%
Aug 5	Chardan Capital	Maintains	Buy → Buy	—	$59.59	$54.30	-8.9%	-6.7%	-5.5%	-6.1%	-7.7%	-7.0%
Jul 22	BofA Securities	Maintains	Buy → Buy	—	$65.33	$64.68	-1.0%	+0.9%	+4.3%	+1.1%	-0.9%	-2.4%
Jul 8	Needham	Maintains	Buy → Buy	—	$51.19	$51.32	+0.3%	+7.1%	+17.4%	+15.3%	+11.0%	+10.2%
Jun 27	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$46.70	$46.72	+0.0%	+1.7%	+4.2%	+3.9%	+10.6%	+11.7%
Jun 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$46.70	$46.72	+0.0%	+1.7%	+4.2%	+3.9%	+10.6%	+11.7%
Jun 27	Piper Sandler	Maintains	Overweight → Overweight	—	$46.70	$46.72	+0.0%	+1.7%	+4.2%	+3.9%	+10.6%	+11.7%
Jun 27	Clear Street	Downgrade	Buy → Hold	—	$46.70	$46.72	+0.0%	+1.7%	+4.2%	+3.9%	+10.6%	+11.7%
Jun 26	Needham	Maintains	Buy → Buy	—	$47.66	$47.33	-0.7%	-2.0%	-0.4%	+2.1%	+1.8%	+8.4%
Jun 26	Chardan Capital	Maintains	Buy → Buy	—	$47.66	$47.33	-0.7%	-2.0%	-0.4%	+2.1%	+1.8%	+8.4%
May 21	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$39.25	$38.80	-1.1%	-5.8%	-4.4%	-6.1%	-4.3%	-5.1%
May 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$38.68	$38.81	+0.3%	+1.5%	-4.4%	-3.0%	-4.7%	-2.9%
May 20	Needham	Maintains	Buy → Buy	—	$38.68	$38.81	+0.3%	+1.5%	-4.4%	-3.0%	-4.7%	-2.9%
May 9	Barclays	Maintains	Equal Weight → Equal Weight	—	$36.14	$36.39	+0.7%	-1.4%	+4.0%	+3.0%	-1.5%	+0.5%
May 8	Goldman Sachs	Maintains	Neutral → Neutral	—	$34.25	$34.88	+1.8%	+5.5%	+4.0%	+9.8%	+8.7%	+3.9%
May 7	Chardan Capital	Maintains	Buy → Buy	—	$33.16	$34.51	+4.1%	+3.3%	+9.0%	+7.4%	+13.4%	+12.2%
May 7	Needham	Maintains	Buy → Buy	—	$33.16	$34.51	+4.1%	+3.3%	+9.0%	+7.4%	+13.4%	+12.2%
Apr 9	Needham	Maintains	Buy → Buy	—	$31.27	$30.56	-2.3%	+11.6%	+9.6%	+25.7%	+24.1%	+24.6%
Feb 19	Cantor Fitzgerald	Maintains	Neutral → Neutral	—	$52.22	$52.40	+0.3%	+1.5%	-3.4%	-8.3%	-10.8%	-14.8%
Feb 18	Citigroup	Maintains	Buy → Buy	—	$49.72	$52.25	+5.1%	+5.0%	+6.6%	+1.4%	-3.6%	-6.3%
Feb 14	Morgan Stanley	Maintains	Underweight → Underweight	—	$43.49	$46.21	+6.3%	+14.3%	+20.1%	+21.9%	+16.0%	+10.2%
Feb 14	Evercore ISI	Upgrade	In Line → Outperform	—	$43.49	$46.21	+6.3%	+14.3%	+20.1%	+21.9%	+16.0%	+10.2%
Feb 13	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$43.30	$43.70	+0.9%	+0.4%	+14.8%	+20.6%	+22.4%	+16.5%
Feb 13	Chardan Capital	Maintains	Buy → Buy	—	$43.30	$43.70	+0.9%	+0.4%	+14.8%	+20.6%	+22.4%	+16.5%
Feb 13	Stifel	Maintains	Hold → Hold	—	$43.30	$43.70	+0.9%	+0.4%	+14.8%	+20.6%	+22.4%	+16.5%
Feb 13	Goldman Sachs	Maintains	Neutral → Neutral	—	$43.30	$43.70	+0.9%	+0.4%	+14.8%	+20.6%	+22.4%	+16.5%
Feb 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.30	$43.70	+0.9%	+0.4%	+14.8%	+20.6%	+22.4%	+16.5%
Feb 12	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$39.62	$40.67	+2.7%	+9.3%	+9.8%	+25.5%	+31.8%	+33.8%
Feb 12	Needham	Maintains	Buy → Buy	—	$39.62	$40.67	+2.7%	+9.3%	+9.8%	+25.5%	+31.8%	+33.8%
Feb 12	Truist	Maintains	Buy → Buy	—	$39.62	$40.67	+2.7%	+9.3%	+9.8%	+25.5%	+31.8%	+33.8%
Feb 12	Barclays	Maintains	Equal Weight → Equal Weight	—	$39.62	$40.67	+2.7%	+9.3%	+9.8%	+25.5%	+31.8%	+33.8%
Jan 14	Needham	Maintains	Buy → Buy	—	$38.85	$39.62	+2.0%	-1.3%	+0.5%	+3.7%	+4.3%	+6.8%

Recent Filings

8-K · 1.01 !! High

Unknown — 8-K 1.01: Material Agreement

CRSP signed a material agreement, but details are incorporated by reference, making immediate impact assessment difficult—investors should review the full filing to understand strategic implications.

Mar 16

8-K · 8.01 !! High

Unknown — 8-K 8.01: Material Event / Announcement

This 8-K filing contains only signature blocks without disclosing the actual material event, leaving investors unable to assess what news CRSP announced or its stock impact.

Mar 11

8-K

CRISPR Therapeutics AG -- 8-K Filing

CRISPR Therapeutics reported full-year 2025 financial results showing steady progress across its pipeline, though specific revenue or earnings impacts require reviewing complete filing details.

Feb 12

Data updated apr 25, 2026 3:21am · Source: massive.com